The Sentinel

THE OFFICIAL BLOG OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC).

Thursday, December 19, 2019

JITC Letter from the Editor - December 2019


pedro-romero_1__1_.jpgDear JITC Readers,

This is the final JITC digest of 2019, and we are ending the year on a historic note with December’s issue containing the most-ever papers published in a single month since the journal’s inception! It has been an exciting year for JITC, and we look forward to what the future holds as the immunotherapy field continues to expand and evolve.

The highlighted papers in this month’s JITC digest truly exemplify some of the most exciting areas of research in our field, spanning preclinical models to human trials and adding new insight into the contribution of the tumor microenvironment to disease progression and immunotherapy resistance as well as the development of novel immunotherapeutic agents.

Be sure to read the Editor Picks below about microenvironment-targeting therapeutics for the reprogramming of myeloid-derived suppressor cells and for the selective depletion of tumor-associated macrophages, gene-edited “off-the-shelf” CAR T cells for the treatment of glioblastoma, preclinical validation for a new checkpoint inhibitor target in ovarian cancer, newly described mechanisms of immunotherapy resistance in melanoma, a deeper understanding of the two types of secondary bone metastases in prostate cancer, and a phase 2 trial describing dendritic cell vaccines for prostate cancer that that induce clinically meaningful immune responses.

With best regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

To view the entire December 2019 JITC Digest, please click here

No comments:

Post a Comment